Chronic Rhinosinusitis With Nasal Polyps Market Report Examines Industry Trends, Growth Drivers And Future Outlook

The chronic rhinosinusitis with nasal polyps (CRSwNP) market is positioned for notable expansion in the coming years, driven by advancements in treatment approaches and growing patient demand for effective therapies. As research progresses and new options emerge, this market is set to experience steady growth through 2030.

Forecasted Growth and Market Size of Chronic Rhinosinusitis With Nasal Polyps
The market size for chronic rhinosinusitis with nasal polyps is projected to reach $6.5 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.0%. This growth is fueled by several factors, including the increasing approvals of monoclonal antibody therapies, heightened investment in ENT (ear, nose, and throat) biologics research, and a rise in outpatient sinus surgeries. Additionally, there is a growing emphasis on preventing disease recurrence and a stronger patient preference for non-surgical treatment options. Emerging trends shaping the market include wider adoption of biologic treatments, the use of minimally invasive surgical techniques, a focus on long-term inflammation management, expansion of personalized treatment plans, and improved integration of diagnostic imaging combined with biomarker-based strategies.

The chronic rhinosinusitis with nasal polyps market size has grown strongly in recent years. It will grow from $4.38 billion in 2025 to $4.78 billion in 2026 at a compound annual growth rate (CAGR) of 9.0%. The growth in the historic period can be attributed to increasing prevalence of chronic sinus disorders, wider use of corticosteroid nasal sprays, growth in ENT specialist consultations, improved diagnostic imaging access, increased awareness of inflammatory sinus diseases.

Download a free sample of the chronic rhinosinusitis with nasal polyps market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17113&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Top Players Driving the Chronic Rhinosinusitis With Nasal Polyps Market
Several key companies play a prominent role in this market, including Pfizer Inc., Roche Holding AG, Merck & Co Inc, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Medtronic plc, Boehringer Ingelheim International GmbH, Amgen Inc, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc, Daiichi Sankyo Company Limited, Olympus Corporation, Eisai Co Ltd, Smith & Nephew PLC, Genentech USA Inc, Mallinckrodt Pharmaceuticals, Lyra Therapeutics Inc, Sunovion Pharmaceuticals, Acclarent Inc., Optinose US Inc, SinuSys Corporation, and Biohaven Pharmaceuticals.

A significant industry development occurred in May 2025, when Paratek Pharmaceuticals, a US-based biopharmaceutical firm specializing in antibacterial and anti-infective therapies, acquired Optinose Inc. Although the financial details were not disclosed, this acquisition supports Paratek's aim to broaden its specialty therapeutics portfolio, enhance commercial strengths, and expand its footprint in respiratory and ENT-focused treatments. Optinose Inc. is well-known for offering therapies targeting chronic rhinosinusitis with nasal polyps.

View the full chronic rhinosinusitis with nasal polyps market report:
https://www.thebusinessresearchcompany.com/report/chronic-rhinosinusitis-with-nasal-polyps-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Emerging Treatment Approaches and Market Trends in Chronic Rhinosinusitis With Nasal Polyps
Leading companies are increasingly concentrating on alternative therapeutic options such as anti-IL-5 biologics to improve patient outcomes and carve out a competitive edge. These biologics target eosinophilic inflammation, which is central to conditions like severe asthma and eosinophilic disorders, thus helping to better control symptoms and improve quality of life.

For example, in March 2024, Optinose received FDA approval for its XHANCE nasal spray, designed specifically to treat chronic rhinosinusitis in adults, including both forms with and without nasal polyps. XHANCE contains fluticasone propionate, a corticosteroid that helps reduce inflammation within the nasal passages. Its unique Exhalation Delivery System (EDS) allows patients to blow into the device while administering the spray, which enhances medication delivery deep into the nasal passages. This targeted delivery effectively reaches areas where nasal polyps grow and sinuses drain, offering more efficient treatment.

Detailed Segmentation of the Chronic Rhinosinusitis With Nasal Polyps Market
This market can be segmented into several categories:

1) By Treatment Type:
- Medications
- Surgical Methods

2) By Route of Administration:
- Nasal
- Oral
- Other Routes

3) By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

Further subsegments include:
- Medications: Corticosteroids (nasal sprays and oral steroids), biologics such as monoclonal antibodies like Dupilumab
- Surgical Methods: Endoscopic Sinus Surgery (ESS), polypectomy (removal of polyps), and balloon sinuplasty

This segmentation helps provide a comprehensive overview of the treatment landscape and delivery methods available for patients managing chronic rhinosinusitis with nasal polyps.

Our 2026 market reports now feature expanded strategic intelligence through market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based dashboards, market hotspots infographics, key technology and future trend analysis, along with updated graphics and tables.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.